Primary tabs
The list of publications is indicative and may not include all publications.
3 Tesla diffusion-weighted MRI for assessing liver fibrosis in nonalcoholic fatty liver disease..
Hepatology. 58(1), 449-50.
(2013).
Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users..
J Addict Med. 7(1), 52-7.
(2013).
Outcome of patients with primary sclerosing cholangitis and ulcerative colitis undergoing colectomy..
World J Gastrointest Pharmacol Ther. 4(3), 61-8.
(2013).
Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship..
Inflamm Bowel Dis. 19(5), 1004-9.
(2013).
Safety of deferasirox in sickle cell disease patients with co-existing liver impairment..
Br J Haematol. 157(4), 505-6; author reply 506-7.
(2012).
Serum lipids in primary sclerosing cholangitis..
Dig Liver Dis. 44(1), 44-8.
(2012).
Long-term outcomes of patients with primary biliary cirrhosis and hepatocellular carcinoma..
Clin Gastroenterol Hepatol. 10(2), 182-5.
(2012).
Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis..
Liver Int. 32(5), 790-5.
(2012).
Pathogenesis and management of pruritus in cholestatic liver disease..
J Gastroenterol Hepatol. 27(7), 1150-8.
(2012).
Virologic response and resistance to lamivudine in patients with chronic hepatitis B: a ten-year retrospective analysis..
Hippokratia. 16(4), 342-6.
(2012).
Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis..
Clin Gastroenterol Hepatol. 9(1), 52-6.
(2011).
The role of sorafenib in downsizing hepatocellular carcinoma prior to liver transplantation and in treating tumor recurrence..
Ann Gastroenterol. 24(3), 228-230.
(2011).
Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma..
Clin Gastroenterol Hepatol. 9(5), 434-9.e1.
(2011).
The clinical presentation of Von Meyenburg complexes..
Hippokratia. 15(2), 170-3.
(2011).
High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis..
Am J Gastroenterol. 106(9), 1638-45.
(2011).
Varices in early histological stage primary biliary cirrhosis..
J Clin Gastroenterol. 45(7), e66-71.
(2011).
High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis..
Aliment Pharmacol Ther. 34(10), 1185-92.
(2011).
Health-related quality of life in Greek chronic hepatitis C patients during pegylated interferon and ribavirin treatment..
Hippokratia. 14(2), 122-5.
(2010).
Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression..
Hepatology. 52(1), 197-203.
(2010).
Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma..
Scand J Gastroenterol. 45(4), 511-2.
(2010).
Treatment options for primary sclerosing cholangitis..
Expert Rev Gastroenterol Hepatol. 4(4), 473-88.
(2010).
Is liver stiffness really unrelated to liver iron concentration?.
Br J Haematol. 150(2), 247-8.
(2010).
Clinicopathological correlations in a series of adult patients with non-alcoholic fatty liver disease..
Pathol Int. 60(2), 87-92.
(2010).
Bile acid profiles in intrahepatic cholestasis of pregnancy: is this the solution to the enigma of intrahepatic cholestasis of pregnancy?.
Am J Gastroenterol. 105(3), 596-8.
(2010).